JAZZJazz PharmaceuticalsSigning up patients
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
H3 K27M · Glioma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 28, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 510 (planned)
- Started
- Jan 23, 2023
- Main results expected
- Jun 2028
- Fully finished
- Jun 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall survival (OS)
Measured over: From date of randomization until date of death from any cause, assessed up to approximately 44 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05580562 · record last updated 2026-04-16 · checked 2026-11-09 15:47 UTC